Literature DB >> 11185744

The BRCA2 genetic variant IVS7 + 2T-->G is a mutation.

M T Pyne1, A R Brothman, B Ward, D Pruss, B C Hendrickson, T Scholl.   

Abstract

Biochemical and genetic characterizations that support the conclusion that the variant BRCA2 IVS7 + 2T --> G represents a deleterious mutation are presented. RNA analysis from a breast cancer patient with BRCA2 IVS7 + 2T --> G showed that the productive message was produced from only one chromosome. A haplotype analysis confirmed that the intronic variant resides on the chromosome that does not produce the normal mRNA. Additionally, an RNA splicing product that deletes exon 7 was produced by the chromosome that carries BRCA2 IVS7 + 2T --> G. The deletion of exon 7 from the RNA alters the open reading frame by removing residues 249-287 and incorporating 18 abnormal amino acids before terminating with an opal stop codon. The experimental approach presented produces strong evidence of the presence of a deleterious mutation, because the contribution by both chromosomes to each RNA species analyzed was tracked using a coding region polymorphism as a marker. Furthermore, a single nucleotide polymorphism (SNP) haplotype analysis that confirms the location of the intronic variant and an associated family history that shows a high incidence of cancer supported these biochemical data.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11185744     DOI: 10.1007/s100380070007

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  7 in total

1.  BRCA2 minor transcript lacking exons 4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation.

Authors:  Eswary Thirthagiri; Kimberly D Klarmann; Anil K Shukla; Eileen Southon; Kajal Biswas; Betty K Martin; Susan Lynn North; Valentin Magidson; Sandra Burkett; Diana C Haines; Kathleen Noer; Roberta Matthai; Lino Tessarollo; Jadranka Loncarek; Jonathan R Keller; Shyam K Sharan
Journal:  Hum Mol Genet       Date:  2016-02-26       Impact factor: 6.150

2.  Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.

Authors:  Blanche P Alter; Philip S Rosenberg; Lawrence C Brody
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

3.  A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.

Authors:  Kajal Biswas; Ranabir Das; Blanche P Alter; Sergey G Kuznetsov; Stacey Stauffer; Susan L North; Sandra Burkett; Lawrence C Brody; Stefan Meyer; R Andrew Byrd; Shyam K Sharan
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

4.  A biochemical analysis demonstrates that the BRCA1 intronic variant IVS10-2A--> C is a mutation.

Authors:  Jessica C Keaton; David R Nielsen; Brant C Hendrickson; Michael T Pyne; Lauren Scheuer; Brian E Ward; Arthur R Brothman; Thomas Scholl
Journal:  J Hum Genet       Date:  2003       Impact factor: 3.172

5.  Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.

Authors:  Ane Y Steffensen; Lars Jønson; Bent Ejlertsen; Anne-Marie Gerdes; Finn C Nielsen; Thomas V O Hansen
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

6.  Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants.

Authors:  Maxime P Vallée; Tonya L Di Sera; David A Nix; Andrew M Paquette; Michael T Parsons; Russel Bell; Andrea Hoffman; Frans B L Hogervorst; David E Goldgar; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2016-04-15       Impact factor: 4.878

7.  Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.

Authors:  Stefan Meyer; Adam Stevens; Roberto Paredes; Marion Schneider; Michael J Walker; Andrew J K Williamson; Maria-Belen Gonzalez-Sanchez; Stephanie Smetsers; Vineet Dalal; Hsiang Ying Teng; Daniel J White; Sam Taylor; Joanne Muter; Andrew Pierce; Chiara de Leonibus; Davy A P Rockx; Martin A Rooimans; Elaine Spooncer; Stacey Stauffer; Kajal Biswas; Barbara Godthelp; Josephine Dorsman; Peter E Clayton; Shyam K Sharan; Anthony D Whetton
Journal:  Cell Death Dis       Date:  2017-06-15       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.